An Open-Label Study of ALTO-100 in Adults With Major Depressive Disorder (MDD)

The company Alto Neuroscience is recruiting for the clinical trial of the ALTO-100 in Major Depressive Disorder.

The condition is Major Depressive Disorder.

The trial officially began on the June 1, 2022 and is planned to complete on May 2023.

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-100.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05419869 or https://clinicaltrials.gov/ct2/show/NCT05419869.

Clinical Research News

Připravované klinické studie

3